Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Authors:
- 3 June 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 27 (18) , 3055-3078
Abstract
As one of the leading and most important metal-based drugs, platinum-based pharmaceuticals are widely used in the treatment of solid malignancies. Despite significant side effects and acquired drug resistance have limited their clinical applications, platinum has shown strong inhibitory effects for a wide assortment of tumors. Drug delivery systems using emerging technologies such as liposomes, dendrimers, polymers, nanotubes and other nanocompositions, all show promise for the safe delivery of platinum-based compounds. Due to the specificity of nano-formulations; unwanted side-effects and drug resistance can be largely averted. In addition, combinational therapy has been shown to be an effective way to improve the efficacy of platinum based anti-tumor drugs. This review first introduces drug delivery systems used for platinum and combinational therapeutic delivery. Then we highlight some of the recent advances in the field of drug delivery for combinational therapy; specifically progress in leveraging the cytotoxic nature of platinum-based drugs, the combinational effect of other drugs with platinum, while evaluating the drug targeting, side effect reducing and sitespecific nature of nanotechnology-based delivery platforms.Keywords
Funding Information
- Department of Science and Technology of Jilin Province (20180101194JC)
- Department of Science and Technology of Jilin Province (20170520149JH)
- Science and Technology Department of Henan Province (182102310611)
- Education Department of Jilin Province (JJKH20170408KJ)
- Program for Jilin University Science and Technology Innovative Research Team (20166032)
This publication has 159 references indexed in Scilit:
- Monofunctional Platinum–DNA Adducts Are Strong Inhibitors of Transcription and Substrates for Nucleotide Excision Repair in Live Mammalian CellsCancer Research, 2012
- Lipoplatin Formulation Review ArticleJournal of Drug Delivery, 2011
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Multistage nanoparticle delivery system for deep penetration into tumor tissueProceedings of the National Academy of Sciences, 2011
- Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination ChemotherapyJournal of the American Chemical Society, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- Activity of lipoplatin in tumor and in normal cells in vitroAnti-Cancer Drugs, 2008
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005